<0> Sales increased 111% to €4.91 million </0>
EOS imaging First Half 2013 Sales More Than Double
EOS imaging+33 (0)1 55 25 61 24orFinancial communication and investor relationsSophie Boulila / Pierre Laurent+33 (0)1 44 71 94 91orPress relations646-536-7012
EOS imaging (NYSE Euronext, FR0011191766-EOSI), the pioneer in orthopaedic 2D/3D imaging, announced today its sales for the first half of 2013.
EOS imaging sales increased 111% to €4.91 million in the first half of 2013 compared with €2.33 million in the same period of 2012.
Sales of systems increased 117% to €4.31 million compared with €1.99 million in the same period of 2012. System sales correspond to the sale of 11 EOS systems during the first half of 2013, compared with 5 EOS systems sold in the same period of 2012. Average sale price per system remained stable at €392,000.
Sales of services were €0.60 million, an increase of 76% due to continued development of systems under maintenance contract.
EOS imaging continued its development in North America, where sales increased 194% to €2.63 million in the first half of 2013 compared with €0.90 million in the same period of 2012. Six EOS systems were sold in North America during the first half of 2013, representing 54% of Group sales, compared with 39% of Group sales in the first half of 2012.
Sales in Europe increased 113% to €2.28 million in the first half of 2013 compared with €1.07 million in the same period of 2012. Five EOS systems were sold in Europe during the first half of 2013.
On a quarterly basis, second quarter 2013 sales increased 70% to €3.01 million compared to €1.77 million in the same period last year. Second quarter 2013 results included the sale of 7 EOS systems, compared with the sale of 4 EOS systems in the same period of 2012.
Marie Meynadier, Chief Executive Officer of EOS imaging, said: ".”
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Backed by an installed base of over 60 sites and more than 350,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group posted 2012 consolidated revenue of €9.42 million and employs 70 people including an R&D team of 25 engineers, and. The Group is based in Paris and holds three subsidiaries in Cambridge (Massachusetts), in Canada at Montreal and in Germany, and offices in Singapore.
For further information, please visit our website at .